Trinity Biotech (TRIB) Stock Statistics & Valuation Metrics

Trinity Biotech has a market cap or net worth of $13.66M. The enterprise value is $107.72M.

Trinity Biotech has 18,632,019 shares outstanding. The number of shares has decreased by -2.65% in one year.

Trinity Biotech’s return on equity (ROE) is 0.90 and return on invested capital (ROIC) is -29.18%.

The current PE Ratio of Trinity Biotech is -0.50. Trinity Biotech’s PEG ratio is 0.01.

In the last 12 months, Trinity Biotech had revenue of 61.55M and earned -31.79M in profits. Earnings per share was -1.80.

In the last 12 months, operating cash flow was -6.20M and capital expenditures -10.06M, giving a free cash flow of -16.26M billion.

Trinity Biotech pays an annual dividend of $1.1, resulting in a dividend yield of ―

Trinity Biotech upcoming earnings date is Sep 2, 2025, TBA (Confirmed).

Trinity Biotech as a current ratio of 1.28, with Debt / Equity ratio of -286.42%

In the past 12 months, Trinity Biotech has paid 486.00K in taxes.

Trinity Biotech EV to EBITDA ratio is -24.36, with an EV/FCF ratio of -28.89.

Trinity Biotech has $5.17M in cash and marketable securities with $100.76M in debt, giving a net cash position of $95.60M billion.

Gross margin is 33.98%, with operating margin of -34.38%, and net profit margin of -51.64%.

The average price target for Trinity Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―